Could a once-daily pill sharpen thinking in older kidney transplant patients?
NCT ID NCT06751992
First seen Nov 18, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This study looks at whether switching to a once-daily anti-rejection drug (Envarsus XR) can improve memory and thinking in older kidney transplant patients compared to staying on a twice-daily drug (Prograf). About 92 people who have had a kidney transplant for at least a year will take part. The goal is to see if the once-daily option helps protect brain function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLD AGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MGH Kidney Transplant Clinic
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.